C4 Therapeutics Inc (NASDAQ:CCCC)’s traded shares stood at 1.1 million during the last session, with the company’s beta value hitting 3.02. At the close of trading, the stock’s price was $5.13, to imply a decrease of -6.90% or -$0.38 in intraday trading. The CCCC share’s 52-week high remains $11.88, putting it -131.58% down since that peak but still an impressive 79.34% since price per share fell to its 52-week low of $1.06. The company has a valuation of $362.13M, with an average of 1.11 million shares in intraday trading volume over the past 10 days and average of 976.78K shares over the past 3 months.
Analysts have given a consensus recommendation of Hold for C4 Therapeutics Inc (CCCC), translating to a mean rating of 1.75. Of 3 analyst(s) looking at the stock, 0 analyst(s) give CCCC a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.37.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
C4 Therapeutics Inc (NASDAQ:CCCC) trade information
After registering a -6.90% downside in the last session, C4 Therapeutics Inc (CCCC) has traded red over the past five days. The 5-day price performance for the stock is -14.07%, and -18.57% over 30 days. With these gigs, the year-to-date price performance is -9.20%. Short interest in C4 Therapeutics Inc (NASDAQ:CCCC) saw shorts transact 5.85 million shares and set a 8.83 days time to cover.
The extremes give us $9 and $20 for target low and target high price respectively. As such, CCCC has been trading -289.86% off suggested target high and -75.44% from its likely low.
C4 Therapeutics Inc (CCCC) estimates and forecasts
Looking at statistics comparing C4 Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. C4 Therapeutics Inc (CCCC) shares are -16.04% down over the last 6 months, with its year-to-date growth rate higher than industry average at 44.57% against 17.10%. Revenue is forecast to grow 46.32% this quarter before jumping 501.24% for the next one. The rating firms project that company’s revenue will grow 69.64% compared to the previous financial year.
Revenue forecast for the current quarter as set by 5 analysts is 3.2M. Earnings reports from the last fiscal year show that sales brought in 3.26M and 3.04M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -1.87% before dropping -100.00% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -36.05% for the past 5-year period. While 2024 is set for a 43.74% return in earnings, projections for the next 5 years are at 22.30% annually.
CCCC Dividends
C4 Therapeutics Inc has its next earnings report out in December. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
C4 Therapeutics Inc (NASDAQ:CCCC)’s Major holders
C4 Therapeutics Inc insiders hold 11.56% of total outstanding shares, with institutional holders owning 87.39% of the shares at 98.80% float percentage. In total, 87.39% institutions holds shares in the company, led by LYNX1 CAPITAL MANAGEMENT LP. As of 2024-06-30, the company held over 6.88 million shares (or 9.9993% of shares), all amounting to roughly $31.79 million.
The next major institution holding the largest number of shares is RA CAPITAL MANAGEMENT, L.P. with 4.88 million shares, or about 7.0891% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $22.54 million.
